Glilor M 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, formulated to manage type 2 diabetes mellitus effectively. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The sustained-release (SR) formulation ensures a gradual and prolonged release of active ingredients, promoting stable plasma concentrations and reducing gastrointestinal side effects commonly associated with immediate-release formulations. Glilor M 2 Tablet SR is indicated for patients inadequately controlled on diet and exercise alone or those who require combination therapy for optimal glycemic management. It is essential to administer this medication with meals to minimize gastrointestinal discomfort. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. This combination therapy should be used as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and exercise, to achieve and maintain target glycemic levels and reduce the risk of diabetes-related complications.